What you need to get Mounjaro on the NHS — and what the criteria actually say

The misconception worth clearing up first: a high BMI alone is not enough

A lot of people come to this question assuming that a BMI above 40 opens an automatic door to NHS Mounjaro. It doesn't. The NICE recommendation for tirzepatide (TA1026) ties eligibility to both a BMI threshold and the presence of multiple weight-related health conditions from a specific qualifying list. The BMI alone (however high) does not meet the criteria on its own. That's worth knowing early, because it changes how you approach the conversation with your GP.

The five qualifying conditions are high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. You can find the phased eligibility detail in full on our guide to whether you can get Mounjaro on the NHS. Meeting the BMI and condition thresholds still doesn't guarantee a prescription, treatment is subject to clinical assessment and to whether your GP practice has opted into the prescribing scheme.

One more thing: the NICE recommendation also requires that patients take part in a wraparound diet and physical activity support programme alongside the medicine. It's part of the deal, not an optional extra.

What the current NHS phases actually require

Phase one, active from June 2025, covers adults with a BMI of 40 or above who have four or more of those five conditions. That is a deliberately narrow starting point; NHS England designed the rollout to manage demand and prioritise the highest clinical need first. For certain ethnic groups (including South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean backgrounds) the BMI threshold is 2.5 kg/m² lower, so 37.5 or above applies in this cohort.

Phase two opened on 23 June 2026 and extends access to adults with a BMI between 35 and 39.9 who still have four or more qualifying conditions. Phase three, expected around March 2027, is planned to lower the condition requirement to three or more at BMI 40-plus. Each phase adds a cohort; it does not replace the previous one. You can read more about the June 2025 launch specifically on our Mounjaro NHS June 2025 page.

From 1 April 2026, GP practices may prescribe tirzepatide under the updated GP contract, but participation is optional. Your surgery may not have signed up yet. Calling your GP to ask is the practical first step, not an assumption that it is available at your practice.

How a GP assessment actually works, and what to bring

If you think you meet the criteria, a conversation with your GP is the right starting point. They will check your BMI, confirm which of the five qualifying conditions appear in your records, and assess whether tirzepatide is clinically appropriate given your full health picture. Certain conditions (a history of medullary thyroid carcinoma, pancreatitis, or multiple endocrine neoplasia type 2) mean tirzepatide is not suitable regardless of BMI or comorbidities.

It helps to arrive informed. Know your most recent BMI figure (the NHS BMI calculator is a simple starting point), and be prepared to discuss which qualifying conditions you have a formal diagnosis for, not just symptoms. Diagnoses on your Summary Care Record carry more weight than self-reported ones in an eligibility conversation. The BMI thresholds for NHS Mounjaro page covers the numbers in more detail if you want to check in advance.

Bear in mind that even where your GP practice participates, they are still carrying out an individual clinical review. Meeting the published criteria is necessary but not automatically sufficient; your prescriber makes the final call.

When NHS criteria aren't met: the private route

The private licensed eligibility for tirzepatide is broader. Adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, may be suitable for a private prescription, subject to clinical assessment. That opens the option to people in the earlier NICE phases, or those whose GP practice hasn't yet adopted the scheme.

For context on what private treatment costs, our Mounjaro cost page explains what legitimate pricing covers and what the market looks like since Eli Lilly adjusted UK list prices in September 2025. The key point is that a private prescription still requires the same clinical rigour: identity verification, a review of your health history, and ongoing clinical oversight before each supply. If you're also wondering about the practicalities of starting treatment, our guide on whether you need to buy needles for Mounjaro covers what comes with the pen and what you may need to source separately. You can read about what getting a Mounjaro prescription involves, whether on the NHS or privately.

At nume, a named GPhC-registered Independent Prescriber reviews every consultation personally. There is no algorithm making that decision. If you'd like to explore whether you're clinically suitable for private treatment while the NHS phases catch up, speak to our prescribers through a free consultation, no commitment, no obligation.